A new computer modeling programme has been devised to help predict the likelihood of complete remission or early death in patients aged 60 years or older undergoing intensive chemotherapy for acute myeloid leukaemia (AML). The findings are reported in an Article Online First and in an upcoming...
Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukaemia (secondary AML)...